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Background: Relative fat-free mass (FFM) deﬁciency (RFFMD) can also occur in obesity, but the impact on left
ventricular (LV) mass is unknown.
Methods:We assessed relations among reduced FFM, obesity and LV mass in a population with high prev-
alence of obesity. Echocardiograms were performed in 2625 participants (1694 women, 1199 non-obese)
of the Strong Heart Study cohort, free of prevalent cardiovascular disease and kidney failure. FFM was es-
timated by bioelectric impedance and analyzed in the non-obese subpopulation in relation with sex, BMI
and waist-to-hip ratio (WHR). RFFMD was estimated in the obese subpopulation as the percent of ob-
served/predicted FFMb20th percentile of the non-obese distribution.
Results: RFFMD was more frequent in women than men. LV mass indices (by either height2.7 or FFM) were
greater in obese with than in those without RFFMD, even after adjusting for sex and diabetes (both
pb0.0001). The greater LV mass index in obesity with RFFMD was related mostly to increased LV diastolic
dimension paralleling increased stroke index and cardiac index, in the presence of normal ejection frac-
tion. RFFMD remained associated with greater LV mass index (pb0.0001) even independently of older
age, greater BMI, higher systolic and lower diastolic blood pressure (all pb0.007), with negligible effect
of sex, waist/hip ratio and diabetes.
Conclusion: In obese SHS participants, RFFMD is associated with higher levels of LV mass, an effect related
to adiposity more than central fat distribution and typical of female gender. Biological mechanisms of this
association have to be better explored.© 2012 Elsevier Ireland Ltd. All rights reserved.1. Introduction
Bone and muscle growth are inﬂuenced by gravity and physical ac-
tivity stimulating mechanoreceptors regulating production of growth
factors [1]. The word “sarcopenia” describes in general the process of
age-relatedmuscle loss and the associated frailty condition [2,3]. Deﬁni-
tion of sarcopenia requires studying body composition and is still con-
troversial [3].
A condition of relative loss of fat-free mass, however, has
been recently recognized in the presence of obesity and called, HL41652, HL41654, HL65521
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Ltd. All rights reserved.“sarcopenic obesity” [4]. The phenotype of sarcopenic obesity strongly
depends on the adopted deﬁnition. Since obese individuals have larger
amount of both fat and lean mass, they usually have a “normal” absolute
quantity of muscle mass, and therefore they do not appear to be
sarcopenic, though their muscle mass might be relatively inadequate for
their size [5]. Thus, higher body mass index (BMI) can mask sarcopenia
[3]. In general, excess energy intake, physical inactivity, low-grade inﬂam-
mation, insulin resistance and changes in hormonalmilieu are thought to
be themain characteristics of sarcopenic obesity [6]. Because sarcopenia is
generally considered a characteristic thatmight increase risk ofmorbidity
in obesity [7], it is of interest to focus on phenotypic characteristics that
might be associated with cardiovacular (CV) risk. Because left ventricular
(LV)mass is substantially inﬂuencedby fat freemass [8], sarcopenia in the
obese individual might be thought to be associated with reduced amount
of LV mass, which might be protective, as LV hypertrophy is the most
potent marker of cardiovascular risk [9]. Speciﬁcally, at present, there is
little characterization of the CV phenotype of sarcopenia in obese
populations. Accordingly, this study has been conceived to assess
Table 1
Variables associated with FFM in the non-obese SHS population.
B p≤ Variance inﬂation
(Constant) 50.92
Arizona center −1.70 0.0001 1.25
Oklahoma center 0.87 0.004 1.29
BMI (kg/m2) 1.23 0.0001 1.16
Waist/hip ratio −2.72 0.24 1.28
Age (years) −0.11 0.0001 1.03
Female gender −15.84 0.0001 1.11
Multiple R=0.89, SEE=4.40 kg.
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mass, in a population of obese men and women.
2. Methods
2.1. Population
The Strong Heart Study (SHS) is a population-based cohort study of CV risk factors
and disease in 4549 American Indians from 3 communities in Arizona, 7 in Southwestern
Oklahoma and 3 in South and North Dakota, which has been extensively described
[10–12]. For the purpose of the present analysis we analyzed participants to the 2nd
exam, which included an echocardiogram (N=3638, 89% of all living); we excluded par-
ticipants who had history or signs of prevalent heart failure or coronary heart disease at
the time of the 2nd SHS exam (ascertained MI or diagnosis of coronary heart disease by
ECG evidence of the previous myocardial infarction – by Minnesota code –, coronary an-
giography, combination of typical symptoms with positive treadmill or imaging stress
tests, or need for revascularization procedures). We also excluded participants with glo-
merularﬁltration rate (GFR)b30 mL/min/1.73 m2, by the simpliﬁedMDRD formula. Prev-
alent CV disease was adjudicated by the Strong Heart Study Mortality and Morbidity
Committees, as previously reported [13]. Thus 2625 participants (1694 women, 1426
obese) were available for the analysis.
The authors of this manuscript have certiﬁed that they comply with the Principles
of Ethical Publishing in the International Journal of Cardiology.
2.2. Laboratory tests and deﬁnitions
Fasting plasma glucose was measured by standard methods. Diabetes (fasting
glucose≥126 mg/dL or ongoing antidiabetic treatment) was diagnosed by the 1997
American Diabetes Association recommendations. Obesity was classiﬁed by the 1998
NIH guidelines (BMI≥30 kg/m2). Waist-to-hip ratio (WHR) was used as a measure
of central fat distribution. Hypertension was deﬁned by the JNC-7 criteria (blood pres-
sure [BP]≥140/90 mm Hg or use of antihypertensive treatment). Insulin resistance
was estimated using HOMA-resistance index [14]. C-reactive protein and ﬁbrinogen
were measured by standard methods. Fat-free mass and adipose body mass were esti-
mated by using an RJL bioelectric impedance meter (model B14101; RJL Equipment
Co.). Equations to estimate fat-free mass (FFM) in kilogram, based on total body
water, using bioelectric resistance, had been previously validated in the American Indi-
an population [15]:
FFMmen ¼ e 1:18log height cmð Þ½ 20:60log resistance½ 10:32log weight kgð Þ½ f g
h i
=0:732
FFMwomen ¼ e 1:20log height cmð Þ½ 20:55log resistance Vð Þ½ 10:22log weight kgð Þ½ f g
h i
=0:732:
The variability of FFM in relation to body mass index, waist-to-hip ratio and gender
was preliminarily estimated in non-obese SHS participants. The multivariable equation
was used thereafter to estimate the predicted theoretical value of FFM in the 1426
obese participants, based on their BMI, waist-to-hip ratio and sex. Thus, observed
FFM was divided by the predicted value (FFMo/p), to assess the relative deﬁcit of FFM
in obese participants.
2.3. Echocardiography
During the 2nd SHS exam, echocardiograms were performed using phased-array
commercial echocardiographs with M-mode, 2-dimensional and Doppler capabilities,
as previously reported [12]. LV dimensions and septal and posterior LV wall thickness
were measured by the American Society of Echocardiography recommendations
[16,17]. LV mass was obtained by an anatomically validated formula and normalized
for body surface area or body height in m2.7 or FFM [18]. Clear-cut LV hypertrophy
was identiﬁed as LV mass index >47.24 g/m2.7, the population speciﬁc cut-point [19]
for both men and women, shown to maximize the population attributable risk in the
SHS cohort. LV volumes were estimated from linear dimensions by the z-derived meth-
od [20] and used to derive stroke volume. Stroke volume and cardiac output were also
normalized (stroke index and cardiac index) by height in meters raised to the speciﬁc
allometric power [21]. Standard methods were used to calculate relative wall thick-
ness, as a measure of LV geometry, and ejection fraction, as a measure of LV systolic
function.
2.4. Statistical analysis
Data were analyzed using the SPSS 17.0 (SPSS, Chicago, IL). Multiple linear regres-
sion analysis was used to analyze the variance of FFM and to extract the relative coef-
ﬁcients of regression of BMI, WHR and sex in the non-obese population. Indicator
variables were included in all multivariate analyses for the three ﬁeld centers, Arizona,
South/North Dakota, and Oklahoma. Multicollinearity was assessed by computing var-
iance inﬂation factor with a conservative pre-speciﬁed limit of 3 to accept the stability
of the model. The distribution of the ratio of observed-to-predicted FFM was analyzed
in the non-obese population and the 20th percentile was arbitrarily assumed as the
partition for deﬁnition of RFFMD. The multivariate equation was used to generate a
predicted value of FFM in the obese population and the 20th normal percentile ofthe observed/predicted ratio was used to identify obese subjects with RFFMD. They
were compared to obese individuals with normal fat-free mass (i.e. >20th percentile).
Descriptive statistics was obtained, using the chi-square distribution for categories
(with Monte Carlo method for computation of exact 2-tailed p value, when appropriate)
and analysis of variance. Analysis of co-variance was used to adjust for relevant con-
founders. Least square linear regression was used to assess univariate relation between
LVmass index and FFMo/p. Multiple linear regression analysiswas used to analyze wheth-
er RFFMDmaintained an independent relation with LV mass index, after adjusting for all
demographic, anthropometric and hemodynamic factors that potentially inﬂuence the
magnitude of LV mass index.
The null hypothesis was rejected at 2-tailed αb0.05.
3. Results
In the group of 1199 non-obese participants, 688werewomen (57%),
437 hypertensive (37%) and 435 diabetic (36%). The average BMI was
26.09±2.75 kg/m2, WHR was 0.94±0.06 and FFM was 48.89±
9.63 kg. Table 1 displays the equation describing the variability of FFM
and the multicollinearity diagnostic. The equation could explain 79% of
the variance of FFM with a standard error of the estimate that was
b10% of the mean. Variance inﬂation factor was b1.3 for all variables,
demonstrating an optimal stability of the model.
As expected, the observed FFM was on average 100% of predicted
(standard deviation was 8.8%). FFMo/p was normally distributed and
the 20th percentile was 93.47%, a value that was used as partition
for arbitrary deﬁnition of relative fat-free mass deﬁciency (RFFMD)
in the obese sub-population.
3.1. Characteristics of obese participants with normal and reduced FFM
Obese participants with RFFMD exhibited the same prevalences of
diabetes (54%) and hypertension (48%) as participants with normal
FFM (55% and 47%). Table 2 shows that reduced FFMwas a characteris-
tic of obese women (59% vs 16% among men, pb0.0001). Participants
with RFFMD had slightly lower mean diastolic BP, greater BMI and
waist girth, but lower WHR (reﬂecting the greater proportion of
women). They also exhibited higher ﬁbrinogen and CRP (all pb0.0001).
3.2. LV geometry and function
LVmasswas smaller in obese participantswith, than in thosewithout
RFFMD (due to the different proportion ofwomen), a difference thatwas
offset when LVmass was normalized for body surface area and reverted
when LV mass was normalized by either height2.7 or FFM (Table 3, both
pb0.0001). These latter differences were also conﬁrmed after adjusting
for sex and the presence of diabetes. The greater LVmass index in obesity
associated with RFFMD was related mostly to increased LV diastolic di-
mension and also to some degree of wall thickening (Table 3). Relative
wall thickness was in fact statistically higher in participants with
RFFMD, but this difference was blunted when adjusting for covariates.
Stroke index and cardiac index were consistently higher in the individ-
uals with RFFMD, paralleling the difference in LV chamber dimension,
with similar ejection fraction.
In the whole obese population, LV mass indexed for height2.7 was
negatively related to FFM as a percent of predicted (r=−0.23,
Table 2
General characteristics of obese SHS participants without or with relative FFM
deﬁciency
Normal FFM
(n=774)
RFFMD
(n=652)
Age (years) 58.7±7.6 58.6±7.3
Sex (% women)‡ 54 90
Systolic BP (mm Hg) 130.4±18.5 130.3±17.9
Diastolic BP (mm Hg)⁎ 76.7±9.9 75.5±9.1
History of hypertension (n[%]) 372 (48%) 313 (48%)
Heart rate (bpm) 72.0±10.6 72.8±10.8
BMI (kg(m2)‡ 34.1±3.6 36.9±5.4
Waist girth (cm)‡ 113.3±9.5 117.9±12.8
WHR‡ 0.98±0.06 0.96±0.05
Fat-free mass (kg)‡ 60.5±12.0 48.8±6.8
GFRMDRD (mL/min/1.73 m2) 84.1±27.1 85.2±31.7
Fibrinogen (mg/dL)‡ 351.4±78.4 381.2±76.9
CRP (mg/dL)‡ 1.36±0.87 1.76±0.93
Abbreviations: RFFMD = relative fat-free mass deﬁciency; BP = blood pressure; BMI =
body mass index; WHR=waist/hip ratio; GFR = Glomerular ﬁltration.
⁎ pb0.02.
‡ pb0.0001.
Table 4
Independent association of relative FFM deﬁciency with LV mass index in obese SHS
participants.
B Beta pb VIF
Age (years) 0.21 0.16 0.0001 1.33
Female gender 1.23 0.06 0.07 1.63
Systolic BP (mm Hg) 0.12 0.22 0.0001 2.04
Diastolic BP (mm Hg) −0.10 −0.09 0.002 1.72
History of hypertension 1.18 0.06 0.05 1.56
BMI (kg/m2) 0.48 0.23 0.0001 1.15
Waist/hip ratio 4.87 0.03 0.33 1.39
Diabetes −0.11 −0.01 0.82 1.09
GFRMDRD (mL/min/1.73 m2) 0.00 0.00 0.96 1.08
Observed/predicted FFM 1.85 0.09 0.0006 1.29
Table 5
Independent association of relative deﬁciency of FFM with LV mass index in obese men
and women of the SHS cohort.
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variables, including older age, marginally greater association with fe-
male gender, greater BMI, history of hypertension, higher systolic BP,
and lower diastolic BP (Table 4), without signiﬁcant multicollinearity.
This multiple regression model was also run separately in men
and women (Table 5). The two models were substantially similar
with small differences largely attributable to the different statistical
power. In both genders, magnitude of LV mass index was indepen-
dently associated with higher systolic and lower diastolic BP, higher
BMI and higher FFM as a percent of predicted (all 0.06bpb0.0001),
with similar regression coefﬁcients. Older age and history of hyper-
tension were more related to LV mass index in women than in men.
4. Discussion
This is the ﬁrst observational study evaluating LV adaptation to obe-
sity in relation with relative FFM deﬁciency, in a large population-
based cohort with high prevalence of obesity. Our attention has been es-
pecially focused on LV mass, which is considered the most potent (and
correctible) marker of cardiovascular risk [9,22,23], recently shown to
be a bioassay also for other harmful cardiovascular CV characteristics, in-
cluding LV geometry and function [24].
Much debate is still ongoing concerning deﬁnition of sarcopenic
obesity [3,5,6]. Similar to what is reported for elderly people, obesity
is often associated with reduced physical activity and energy expendi-
ture, which favor further accumulation of abdominal fat [25], worsening
insulin resistance and enhancing the inﬂammatory response associated
with visceral fat [26]. Inﬂammatory markers have been reported to be
negatively associated with the amount of muscle mass [27,28] andTable 3
Raw and adjusted differences in LV geometry, function and performance between par-
ticipants without or with relative FFM deﬁciency.
Normal FFM
(n=774)
RFFMD
(n=652)
p≤ ⁎Adjusted
p≤
LV dimension index (cm/m) 3.04±0.26 3.13±0.27 0.0001 0.0001
LV mass (g) 170.1±39.0 155.3±31.3 0.0001 0.004
LV mass index (g/m2.7) 42.2±9.7 45.7±9.8 0.0001 0.0001
LV mass/FFM (g/kg) 2.86±0.67 3.22±0.69 0.0001 0.0001
LV mass/BSA (g/m2) 83.06±17.80 81.41±16.21 0.07 0.76
Relative wall thickness 0.348±0.043 0.354±0.043 0.009 0.455
Ejection fraction (%) 64.5±5.9 65.4±5.5 0.003 0.496
Stroke index (mL/m2.04) 26.4±4.3 28.3±4.4 0.0001 0.0001
Cardiac index (L/min/m1.83) 1.97±0.39 2.11±0.41 0.0001 0.0001
Abbreviations: FFM = fat-free mass.
⁎ Adjusted for ﬁeld center, sex and presence of diabetes.both interleukin-6 and C-reactive protein are predictors of loss of lean
mass in middle-age men and women [29]. Other inﬂammatory cyto-
kines produced in the visceral fat participate to the loss of lean mass,
such as tumor necrosis factor-α and leptin [5]. Our ﬁndings are very
consistent with this scenario, as C-reactive protein was substantially in-
creased in SHS participants with RFFMD.
Thus, in obesity the loss of fat-free mass is constantly associated
with further accumulation of fat. The method that we used to quanti-
fy relative FFM deﬁciency in the context of an unselected population
with high prevalence of obesity allowed to account at least in part
for the known increase in FFM occurring with obesity and making un-
realistic the evaluation of sarcopenia based on the raw assessment of
FFM. Our method is consistent with the predominant trend to consid-
er FFM in relation to adipose mass [6] and has the advantage of being
targeted on the speciﬁc studied population. It is suggested that, in the
context of obesity, sarcopenia be considered as a condition of abnor-
mal body composition, altering a normal balance between fat and
fat-free mass [3,5]. Accordingly, sarcopenia in obesity might be better
deﬁned as a “relative FFM deﬁciency”. A novelty of our approach is
the consideration of the amount of fat-free mass as related not only
to the measure of obesity (BMI) but also to central fat distribution
(WHR), sex and age, all factors that have been related to sarcopenia.
The predictive equation developed in the non-obese population of
the SHS was applied in the obese SHS sub-population and gave sur-
prising results.
In the SHS population, a relative FFMdeﬁciency in the context of obe-
sity is revealed to be mostly a feminine characteristic. Only 16% of male
participants were classiﬁed as sarcopenic, compared to 58% of women.
There is no mechanistic explanation of this difference, which cannot be
provided by the present cross-sectional analysis, but this ﬁnding is in
line with both the evidence of less fat-free mass in women in bothMen (n=67) Women (n=585)
B Beta pb VIF B Beta pb VIF
Age (years) 0.14 0.11 0.03 1.22 0.24 0.18 0.0001 1.37
Systolic BP
(mm Hg)
0.13 0.27 0.0001 1.87 0.11 0.20 0.0001 2.16
Diastolic BP
(mm Hg)
−0.10 −0.12 0.05 1.78 −0.09 −0.07 0.04 1.58
History of
hypertension
0.16 0.01 0.87 1.46 1.58 0.08 0.04 1.62
BMI (kg/m2) 0.54 0.24 0.0001 1.14 0.47 0.23 0.0001 1.17
Waist/hip ratio 2.56 0.02 0.76 1.25 5.93 0.03 0.35 1.09
Diabetes −0.48 −0.03 0.57 1.13 0.02 0.00 0.97 1.09
GFRMDRD
(mL/min/
1.73 m2)
0.01 0.05 0.32 1.10 −0.01 −0.02 0.55 1.06
Observed/
predicted FFM
2.08 0.09 0.06 1.06 1.82 0.09 0.004 1.14
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of females to increase their lean body mass under growth hormone re-
placement therapy, compared with males [33].
Obese participants with relative FFM deﬁciency in the present
study exhibited anthropometric measures consistent with the large
proportion of women, with lower WHR, but greater waist girth,
reﬂecting both gynoid fat accumulation and central fat distribution.
As a consequence of the relative FFM deﬁciency identiﬁed in 46% of
the SHS obese participants, decreased LV mass and LV mass indices
could be expected. Unindexed LV mass was in fact lower in these in-
dividuals, but this was entirely due to the greater proportion of
women. This difference was expectedly offset by normalization with
body surface area, which is known to severely underestimate the im-
pact of obesity on LV geometry [19,34]. In contrast, when normalized
for either height2.7 or fat free-mass, LV mass index was substantially
greater in the subgroup with RFFMD than in the group of obese sub-
jects with normal body composition. This ﬁnding provides a further
potential explanation for our previous analysis, demonstrating that
in the SHS cohort, obese women exhibit values of LV mass index
greater than obese men [31], a difference that the model of regression
shown in Table 4 indicates might be substantially related to the great-
er relative FFM deﬁciency, which obscures the gender effect previous-
ly detected. Myocardial composition is different in men and women
and this difference increases with aging, because myocardial fat
metaplasia occurs in women [35]. This ﬁnding is consistent also
with the evidence that, though the independent association of LV
mass index with FFM as a percent of predicted is of similar magnitude
in men and women (with statistical signiﬁcance difference due to the
different cell size), older age is substantially more important in
women than in men, conﬁrming also the data from the Framingham
Heart Study [36].
In the analysis previously performed [31], central adiposity emerged
as a leading correlate of greater LVmass, whereas, in the present analy-
sis, including the relative deﬁcit of fat-free mass, central fat distribution
(evaluated by WHR) did not show independent association with LV
mass index, suggesting that the deﬁciency of fat-free mass might be at
the basis of the previously detected relation between LV mass index
and central fat distribution [37].
Because LVmass ratiometrically normalized for fat-freemass (aswell
as for the allometricmeasure of body height) is increased in the presence
of relative FFM deﬁciency, it is unlikely, though not impossible, that this
increase be due to a disproportionate growth of cardiomyocytes. Other
myocardial tissue components are likely to be involved, namely fat. Fat
might contribute together with the other cell components of myocardi-
um to determine the magnitude of LV mass when obesity is associated
with signiﬁcant loss of FFM. This possibility is supported by the previous
evidence.
Fat inﬁltration in the heart of obese subjects, especially those with
visceral adiposity, has been demonstrated in obese individuals, char-
acterized by a disarray of myocardial composition (Virchow's “fatty
atrophy” of the heart), with fat accumulation and relative reduction
of active muscle mass [38–40].
Our results also conﬁrm that adipose mass is directly related to LV
hypertrophy and, at the cardiac level, masks the loss of FFM that oc-
curs in a high proportion of obese individuals. Because the difference
in FFM between men and women is conﬁrmed also in the SHS popu-
lation [31], the paradox effect of relative FFM deﬁciency on LV geom-
etry in the context of obesity might be especially important in women
to explain their increased magnitude of LV mass, a ﬁnding that is
supported by the previous evidence [41,42], but also requires more
investigation.
4.1. Study limitations
Two potential limitations should be considered. While the condi-
tion of “sarcopenia” is well described in elderly population, as itimplies loss of muscle mass and frailty [3], it is not yet certain in the
context of obesity, and many different approach have been attempted
[2–4,43]. We have generated a method that accounts for major corre-
lates in normal conditions and implicitly adjusts for them in non-
physiological conditions. While we may not have the best method,
this approach accounts in part also for the second potential limitation
of the study, its conduct in a single ethnic population. Even considering
that our ﬁndings may not necessarily be extrapolated to other ethnic
groups, the method to assess relative FFM deﬁciency does not refer to
partition values extracted from other reference populations, whereas,
rather, the deﬁciency is measured based on individual variables. This
approach is very similar to what has been done previously to evaluate
the compensatory or not compensatory nature of LV mass in Caucasian
populations [44].4.2. Conclusion
Obesity with relative FFM deﬁciency is associated with higher
levels of LV mass, an effect related to general adiposity more than
central fat distribution and typical of female gender. Mechanisms of
this association have to be explored.Acknowledgments
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